Dr. Michael Girvigian, MD

Dr. Girvigian practices at Southern California Permanente Medical Group in Los Angeles, California.

Dr. Girvigian's NPI, 1215008289, was assigned on November 13, 2006. Dr. Girvigian graduated from Drexel University College Of Medicine in 1997. Dr. Girvigian holds California license A68225.

Dr. Girvigian's primary practice is Southern California Permanente Medical Group, at 4760 W Sunset Blvd, Los Angeles, CA 90027 in Los Angeles County. The practice phone is (323) 783-4011.

Dr. Girvigian's primary practice is Southern California Permanente Medical Group in Los Angeles, California. The medical group on file is Southern California Permanente Medical Group. Dmand AI also links Dr. Girvigian to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Girvigian practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Girvigian's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Girvigian is board certified in radiation oncology by the American Board of Radiology. Dr. Girvigian is licensed in California.

Dmand AI lists breast cancer radiation among the conditions Dr. Girvigian treats.

CMS data shows 18 Medicare services from Dr. Girvigian across 1 procedure code in 2016, for 16 Medicare patients. Medicare paid $4,185 for them. Every service was in an office.

CMS counts 16 Medicare patients who saw Dr. Girvigian in 2024. 75% of them have cancer. Their average risk score is 1.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Girvigian's median patient age at 69, with 49% women.

In 2024, Dr. Girvigian wrote 75 Medicare Part D claims for 43 patients. 89% of them were for generic drugs. CMS names the drug for 15 of them, across 1 drug with 11 or more claims each, at $219 in total drug cost. In 2023, CMS named 37 claims across 3 drugs.

Dr. Girvigian accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Dr. Girvigian, published from 2016 to 2018. Dr. Girvigian's most frequent co-authors are Kenneth Lodin, MD, Joseph C. Chen, MD and Eric Chi-Ching Ko, MD, PhD.

Dmand AI links Dr. Girvigian to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Tongue Neoplasms and Tongue Diseases.

CMS Open Payments shows 56 general payments to Dr. Girvigian from 15 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Siemens Medical Solutions USA, Inc. paid the most, $901.

Dr. Girvigian graduated from Drexel University College Of Medicine in 1997.

Dr. Girvigian is in network with 2 carriers, including CMS Medicare and Kaiser Permanente. EPO plans come from the most carriers, 1. Check the plan with the practice before a visit.